Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 15/20 | 0.99 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 0.99 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.99 |
| ▸ | RECQL | P46063 | 1/20 | 0.99 |
| ▸ | BLM | P54132 | 1/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | EGFR | P00533 | 1/20 | 0.99 |
| ▸ | ESR1 | P03372 | 1/20 | 0.99 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.99 |
| ▸ | FYN | P06241 | 1/20 | 0.99 |
| ▸ | PGR | P06401 | 1/20 | 0.99 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.99 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.99 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.99 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.99 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.99 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL41733 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4752437 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL27474743 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL125179 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL15375392 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4788144 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4487 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4486 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL22207045 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL21635556 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116492315-A | Montelukast sodium microcapsule, preparation method and application thereof | 郑州大学第一附属医院 | 2023-07-28 | — | — | CN | disclosed |
| CN-109503476-A | A kind of synthesis technology of Montelukast Sodium | 哈尔滨珍宝制药有限公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-1968943-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LAB LTD (IN) | 2013-01-23 | — | — | EP | disclosed |
| US-8178680-B2 | Process for the preparation of Montelukast and its pharmaceutically acceptable salts | MSN LABORATORIES LIMITED (IN) | 2012-05-15 | — | — | US | disclosed |
| WO-2012020271-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM | RICHTER GEDEON NYRT. (HU) | 2012-02-16 | — | — | WO | disclosed |
| EP-2231613-B1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2011-10-12 | — | — | EP | disclosed |
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100069641-A1 | PROCESS FOR THE PREPARATION OF SODIUM SALT OF 1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2010-03-18 | — | — | US | disclosed |
| US-7572930-B2 | Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof | CHEMAGIS LTD. (IL) | 2009-08-11 | — | — | US | disclosed |
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | MSN LABORATORIES LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| US-20080009629-A1 | Novel Form of a Benzenesulfonamide Derivative | PLIVA-ISTRAZIVANJE I RAZVOJ D.O.O. (HR) | 2008-01-10 | — | — | US | disclosed |
| US-20070213365-A1 | Novel polymorphs of montelukast ammonium salts and processes for preparation therefor | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20070208177-A1 | Novel process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096875-A2 | NOVEL POLYMORPHS OF MONTELUKAST AMMONIUM SALTS AND PROCESSES FOR PREPARATION THEREFOR | CHEMAGIS LTD. (IL) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007088545-A2 | NOVEL PROCESS FOR PREPARING 1-(MERCAPTOMETHYL) CYCLOPROPANEACETIC ACID, A USEFUL INTERMEDIATE IN THE PREPARATION OF MONTELUKAST AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2007-08-09 | — | — | WO | disclosed |
| EP-1429843-B1 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-20060223999-A1 | Process for preparing montelukast and precursors thereof | CHEMAGIS LTD. (IL) | 2006-10-05 | — | — | US | disclosed |
| US-20050187245-A1 | Stable amorphous forms of montelukast sodium | CHEMAGIS LTD. (IL) | 2005-08-25 | — | — | US | disclosed |
| US-20050014762-A1 | Combination | NYCOMED GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213365-A1 | Novel polymorphs of montelukast ammonium salts and processes for preparation therefor | ATP6V1A, ATP6V1H, ATP6V1G1 | CYSLTR1 27/4885CYSLTR2 103/4885CYP2C8 614/4885 |
| US-20060223999-A1 | Process for preparing montelukast and precursors thereof | CMA1, LTC4S, LTB4R2 | CYSLTR1 16/4885CYSLTR2 5/4885CYP2C8 718/4885 |
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | CMA1, TPSD1, AP1S1 | CYSLTR1 23/4885CYSLTR2 32/4885CYP2C8 676/4885 |
| US-20050187245-A1 | Stable amorphous forms of montelukast sodium | CMA1, MAST3, LTC4S | CYSLTR1 20/4885CYSLTR2 17/4885CYP2C8 3957/4885 |
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | CMA1, CYSLTR2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 2/4885CYP2C8 1004/4885 |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CYSLTR2, MPST, CMA1 | CYSLTR1 4/4885CYSLTR2 1/4885CYP2C8 1092/4885 |
| US-20050014762-A1 | Combination | PDE4A, PDE4B, PDE3B | CYSLTR1 23/4885CYSLTR2 20/4885CYP2C8 1038/4885 |
| US-20070208177-A1 | Novel process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof | CMA1, CYSLTR1, MPST | CYSLTR1 2/4885CYSLTR2 5/4885CYP2C8 1018/4885 |
| US-20100069641-A1 | PROCESS FOR THE PREPARATION OF SODIUM SALT OF 1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID | SLC7A1, CLIC1, TMT1A | CYSLTR1 1267/4885CYSLTR2 1917/4885CYP2C8 2230/4885 |
| US-20080009629-A1 | Novel Form of a Benzenesulfonamide Derivative | ADH1A, ADH5, ADH1C | CYSLTR1 3773/4885CYSLTR2 3571/4885CYP2C8 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.